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Summary
Objective Corticosteroids are commonly used for treating nerve damage in leprosy.
We assessed the effectiveness of corticosteroids for treating nerve damage due to
leprosy.
Methods A systematic search was undertaken to identify randomised controlled
trials (RCTs) comparing corticosteroids with placebo or with no treatment. Two
authors independently assessed quality and extracted data. Where it was not possible
to perform a meta-analysis, the data for each trial was summarised.
Results Three RCTs involving 513 people were found. Two trials compared
prednisolone with placebo. One trial treated mild sensory impairment of less than
6 months duration and the other trial treated nerve function impairment of 6 to
24 months duration. Both trials examined nerve function improvement 12 months
from the start of treatment, but found no significant difference between the two
groups. The third trial compared three corticosteroid regimens for severe type
1 reactions. After 12 months, a significantly higher proportion of individuals on a
3 month course required extra corticosteroids compared to the groups with a
high-dose and low-dose regimen of 5 months duration. Diabetes and peptic or
infected ulcers were not significantly more often reported in the corticosteroid
compared to the placebo group.
Conclusions Evidence from RCTs does not show a significant long-term effect for
either long-standing nerve function impairment or mild sensory impairment. A 5
month corticosteroid regimen was significantly more beneficial than a 3 month
corticosteroid regimen. Further RCTs are needed to establish the effectiveness and
optimal regimens of corticosteroids and to examine new therapies.
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Introduction
This paper is based on a Cochrane review first published in The Cochrane Library 2007,
Issue 2 (see http://www.thecochranelibrary.com/ for information). Cochrane reviews are
regularly updated as new evidence emerges and in response to feedback, and The Cochrane
Library should be consulted for the most recent version of the review.
Corticosteroids, especially prednisolone, are commonly used for treating severe reactions
and nerve damage in leprosy. They work by controlling acute inflammation and relieving
pain.1,2 The earlier corticosteroids are given after the onset of nerve damage, the more likely
permanent nerve function impairment will be prevented.3,4 The recommended corticosteroid
regimen for treating nerve damage starts with 40 mg prednisolone daily and lasts for
12 weeks.5 Studies indicate that prolonged prednisolone treatment may be more effective in
treating severe reactions and nerve damage.3,6 – 8 Prednisolone seems to be a very effective
drug, but it has some shortcomings. Long-term therapy may cause serious adverse effects,
such as peptic ulcers, cataracts, or psychosis.9 – 11 A considerable proportion of people treated
for nerve damage does not benefit from corticosteroid treatment.12 – 15 Other therapies for
improving nerve function and relieving nerve pain, such as surgical decompression of
nerves,16 – 18 azathioprine,19 and ciclosporin,20 have been tested. These interventions are
beyond the scope of this review.
Corticosteroids are the drugs of choice for acute severe reactions and nerve damage, but
the long-term effect of corticosteroids is uncertain and the optimal regimen has not been
established. While this review focused on evidence from randomised controlled trials
(RCTs), it was expected that only a few RCTs have been conducted in this area. Therefore,
the results have also been considered in the light of non-randomised evidence in the
Discussion section.
Methods
SEARCH STRATEGY
We searched the Cochrane Neuromuscular Disease Group Register using the following
terms: (leprosy or Hansen disease or Hansen’s disease) AND (steroid* or corticosteroid* or
glucocorticoid* or (cortical hormone*) or prednison* or prednisolon* or cortison*) AND
(exp peripheral nervous system diseases) or neuritis or neuropath* or (nerve damage) or
(nerve involvement) or (nerve loss) or (nerve function impairment) or (nerve problem*) or
(sensory loss) or (motor loss) or (nerve pain) or (nerve tenderness) or reaction*. This search
strategy, combined with a search strategy for identifying randomised trials, was adapted to
include additional search terms where necessary and was modified to search the Cochrane
Central Register of Controlled Trials (Cochrane Library, Issue 4, 2005), MEDLINE (from
1966), EMBASE (from 1980), CINAHL (from 1980) and LILACS (from 1982) in January
2006. References from trials and conference proceedings were searched. Trial authors were
contacted and the Current Controlled Trials Register (www.controlled-trials.com) was
searched for ongoing trials. There were no language restrictions. Two authors independently
screened the titles and abstracts of all the publications identified to examine whether studies
were eligible.
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STUDY SELECTION
Studies were eligible if they were (quasi-) randomised controlled trials (RCTs) assessing
corticosteroids versus placebo or no treatment for patients with leprosy and related nerve
damage or severe leprosy type 1 reaction, requiring corticosteroid treatment. Nerve damage
or nerve function impairment (NFI) was defined as clinically detectable impairment of motor
or sensory nerve function. It did not include impairment of nerve conduction that was only
detectable by electrophysiological means.21 Outcome measures of interest were:
improvement in sensory nerve function as measured with graded nylon filaments22 or a
ball-point pen after 1 or 2 years, improvement in motor nerve function, assessed with the
modified MRC grading scale 23 after 1 or 2 years, change in nerve pain and tenderness after
1 year, and adverse events requiring withdrawal from treatment.
METHODOLOGICAL QUALITY
The methodological quality of the included studies was based on the following criteria:
concealment of allocation; blinding of participants and outcome assessors; loss to follow-up;
clear diagnosis; baseline differences and explicit outcome measures mentioned.
Each criterion was assessed as ‘A’: adequate, ‘B’: unclear or ‘C’: inadequate. If one of the
criteria was not described in the study, it was labelled ‘inadequate’. Concealment of
allocation was considered adequate if the randomisation process prevented the individual
making the allocation from foreseeing the treatment assignment. Blinding was considered
adequate if participants and outcome assessors were unaware of the treatment given. Follow-
up was considered adequate if the loss to follow-up was less than 10%. Two authors
independently assessed the included studies for methodological quality.
DATA EXTRACTION AND ANALYSIS
Two authors extracted data regarding methodology and outcome measures from the included
studies onto a data extraction form. If there were missing data, the trial authors were
contacted. Authors were not blinded to trial author, journal or institution. We used
the Cochrane statistical package, Review Manager, for statistical data analysis. Results were
expressed as mean differences with 95% confidence intervals (CI) for continuous outcome
measures and relative risks (RR) with 95% CI for dichotomous outcomes. In case of clinical
heterogeneity, or if data were lacking, the results for each trial were summarised. We
analysed separately participants with NFI of less than 6 months duration and participants with
long-standing impairment (6 to 24 months duration). Adverse effects were expressed as the
proportion of participants with major adverse events.
Results
STUDY SELECTION
We identified 10 potentially relevant studies and excluded eight, because they were not
randomised, compared corticosteroids plus a complementary therapy versus corticosteroids,
or focused on prevention of nerve damage. One RCT became available during the review
process. In total, we found three RCTs for this review.
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INTERVENTIONS
Two studies compared corticosteroids with placebo. One of them compared prednisolone
with placebo in participants with mild sensory NFI.24 The other trial compared prednisolone
with placebo in participants with long-standing NFI.25 One study compared three different
corticosteroid regimens.26 This trial compared high dose corticosteroids versus low dose
corticosteroids versus short regimen corticosteroids for participants with severe type
1 reactions.
OUTCOME MEASURES
The two trials comparing corticosteroids with placebo assessed improvement of nerve
function 1 year after the start of treatment. Improvement was measured as either a change
score between baseline and end of follow-up or as the proportion of participants improved.
Change in nerve pain and nerve tenderness was not measured in these trials. Adverse events,
requiring withdrawal of treatment were reported in both trials.
None of the pre-specified outcome measures were evaluated in the trial comparing three
different corticosteroid regimens. The primary endpoint was the requirement for additional
corticosteroids during the 12 month trial period. A poor outcome was defined as a failure to
respond to treatment in terms of changes to skin lesions, nerve pain or tenderness, or nerve
function, or recurrences of skin or nerve lesions and needing extra corticosteroids.
METHODOLOGICAL QUALITY
The results of the assessment of methodological quality are shown in Table 1.
Randomisation and blinding were considered adequate in all three trials. Loss to follow-
up varied from 3% to 19%. Leprosy was diagnosed and classified using skin smear or number
of skin lesions. Baseline characteristics in the different groups were similar. Nerve function
improvement after 1 year was reported in two trials, but not after 2 years. Change in nerve
pain and nerve tenderness was not measured in any of the trials. Adverse events occurred in
two trials.
CORTICOSTEROIDS VERSUS PLACEBO FOR PARTICIPANTS WITH MILD SENSORY
NERVE FUNCTION IMPAIRMENT (NFI ) OF LESS THAN 6 MONTHS DURATION 24
Results were available for 89% (75/84) of the participants. After 12 months the mean change
in sensory score was 22·68 ^ 2·66 in the prednisolone group and 23·00 ^ 2·75 in the
placebo group both implying a mean improvement. The improvement was slightly greater in
the placebo group but the mean difference 0·32 (95% CI 20·91 to 1·55) between the two
groups was not significant. The proportion with sensory improvement was 80% (33/41) in
the prednisolone group compared with 79% (27/34) participants in the placebo group. The
difference was not significant. Major adverse events were reported in two participants. One
person was diagnosed with diabetes (prednisolone) and one with an infected ulcer (placebo).
N. H. J. van Veen et al.364
Table 1. Characteristics of included studies. From Van Veen, et al. Cochrane Database Sys Review 2007; CD005491; with permission
Study Methods Participants Interventions Outcomes Results Notes
Rao 2006 Randomised,
parallel group
trial
334 leprosy patients with
severe type 1 reactions
requiring steroid treatment
(a) Prednisolone start at
60 mg/day and thereafter
gradually tapered with 10 or
5 mg/2 or 4 weeks until 5
months completed (total
3500 mg)
Requirement for additional
corticosteroids during the 12-
month trial period
No data Multicentre
Conducted in six
centres in India
Externally
controlled
computer
randomisation
Persons randomised: 334 (b) Prednisolone start at
30 mg/day and thereafter
gradually tapered with 5 mg/2,
4 or 8 weeks until 5 months
completed (total 2310 mg)
Double blind Persons analysed: 269 (a: 88, b:
91, c: 90)
(c) Prednisolone start at
60 mg/day and thereafter
gradually tapered with 20 or
10 mg/2 weeks until 3 months
completed (total 2940 mg) plus
2 months placebo
Richardus
2003
Randomised,
parallel group
trial
95 leprosy patients with
confirmed MB leprosy
diagnosis having untreated
sensory or motor impairment of
the ulnar or posterior tibial
nerve of more than 6 months up
to 24 months of duration
(a) Prednisolone start at
40 mg/day and thereafter
gradually tapered with 5 mg/2
weeks until 16 weeks
completed (total 2520 mg)
Sensory improvement (SI) after
1 year, motor improvement
(MI) after 1 year, occurrence of
major adverse events
Change in SI:
MD ¼ 0·42
(95%CI 20·57;
1·41)
Multicentre
Conducted in
Nepal and
Bangladesh
Externally
controlled
computer
randomisation
Unit of randomisation: person (b) Placebo, equivalent number
of tablets for 16 weeks
% with SI:
RR ¼ 0·97
(95%CI 0·65; 1·45)
Double blind Unit of analysis: ulnar or
posterior tibial nerve
Change in MI:
MD ¼ 0·12
(95%CI 20·76;
1·00)
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Table 1. continued
Study Methods Participants Interventions Outcomes Results Notes
Of participants with bilateral
nerve function impairment, the
scores of the most affected limb
were used in the analysis. If
both limbs were equally
affected, then the scores of the
right side were used in the
analysis
% with AE:
RR ¼ 1·87 (95%
CI 0·33; 10·64)
Persons randomised: 95
Nerves analysed: 92 (a: 41,
b: 51)
Van
Brakel
2003
Randomised,
parallel group
trial
84 leprosy patients with
confirmed MB leprosy
diagnosis having sensory
impairment of the ulnar or
posterior tibial nerve of less
than 6 months duration
(a) Prednisolone start at
40 mg/day and thereafter
gradually tapered with 5 mg/2
weeks until 16 weeks
completed (total 2520 mg)
Sensory improvement (SI) after
1 year, occurrence of major
adverse events (AE)
Change in SI:
MD ¼ 0·32
(95%CI 20·91;
1·55)
Multicentre
Conducted in
Nepal and
Bangladesh
Externally
controlled
computer
randomization
Unit of randomisation: person (b) Placebo, equivalent number
of tablets for 16 weeks
% with SI:
RR ¼ 1·01
(95%CI 0·81; 1·27)
Double blind Unit of analysis: ulnar or
posterior tibial nerve
% with AE:
RR ¼ 0·83 (95%
CI 0·05; 12·77)
TRIPOD 2
Of participants with bilateral
nerve function impairment, the
scores of the most affected limb
were used in the analysis. If
both limbs were equally
affected, then the scores of the
right side were used in the
analysis
Persons randomised: 84
Nerves analysed: 75 (a: 41, b:
34)
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CORTICOSTEROIDS VERSUS PLACEBO FOR PARTICIPANTS WITH LONG-
STANDING NERVE FUNCTION IMPAIRMENT (NFI ) OF 6 TO 24 MONTHS DURATION 25
Results were available for 94% (89/95) of the participants. After 12 months the mean
difference in sensory score was 21·25 ^ 1·66 in the prednisolone group and 21·67 ^ 3·02
in the placebo group indicating a mean improvement in both. The improvement was slightly
greater in the placebo group but the mean difference 0·42 (95% CI 20·57 to 1·41) between
the two groups was not significant. The proportion with sensory improvement was 57%
(17/30) in the prednisolone group compared with 59% (24/41) in the placebo group (results
available for 71 participants). The difference was not significant (relative risk 0·97, 95% CI
0·65 to 1·45). Results of motor nerve function were available for 21 participants. Of these
21 participants, three had motor NFI only and 18 had both sensory and motor NFI. After
12 months the mean difference in motor score was 20·18 ^ 0·98 in the prednisolone group
and 20·30 ^ 1·06 in the placebo group both indicating a mean improvement. The
improvement was slightly greater in the placebo group but the mean difference 0·12 (95% CI
20·76 to 1·00) between the two groups was not significant.
Five participants came out of the trial due to symptoms of possible major adverse events.
Three of them were in the prednisolone group (diabetes, infected ulcer, ‘hypersensitivity’ to
the tablets), and the other two were assigned to placebo treatment (diabetes, peptic ulcer).
HIGH DOSE CORTICOSTEROIDS VERSUS LOW DOSE CORTICOSTEROIDS VERSUS
SHORT REGIMEN CORTICOSTEROIDS FOR PARTICIPANTS WITH SEVERE TYPE 1
REACTIONS 2 6
At the end of the 12 month period, 41 out of 90 participants (46%) in the short course group
(2940 mg over 3 months) needed extra corticosteroids. In the group of participants receiving a
low dose of prednisolone (2310 mg over 5 months) this was 28 out of 91 (31%) and 21 out of
88 participants (24%) following a high dose prednisolone regimen (3500 mg over 5 months)
required additional prednisolone. The difference between the high dose and low dose 5 month
regimen was not significant (relative risk 0·78, 95% CI 0·48 to 1·26). The relative risk of
needing additional corticosteroids was significantly less with the high dose 5 month course
than with the 3 month course (relative risk 0·52, 95% CI 0·34 to 0·81). The relative risk of
needing additional corticosteroids was just significantly less with the low dose 5 month
course than with the 3 month course (relative risk 0·68, 95% CI 0·46 to 0·99). No major
adverse events were reported during the follow-up period of this trial.
Discussion
Three randomised controlled trials were available for this review. The interventions and
outcomes were too heterogeneous to be entered in a meta-analysis. The numbers of
participants included in the trials were small and did not allow for subgroup analysis.
The variability between studies and the limitations in sample size made it difficult to draw
any robust conclusions. None of the trials found a significant difference in improved nerve
function between treatment and control group 12 months after the start of treatment. The
question, whether corticosteroids are beneficial in treating acute NFI or type 1 leprosy
reaction in a field setting in the longer term compared to placebo, remains unclear.
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Several non-randomised studies have examined the effect of corticosteroids for treating
severe reactions and nerve damage in leprosy. The response to corticosteroid treatment seems
to depend on the severity and duration of NFI before the start of treatment.
One study found that 35% of patients having complete anaesthesia and 67% with
moderate sensory impairment improved to good function 3 months after the start of
corticosteroid treatment. For patients with complete motor paralysis or moderate motor
impairment, respectively 11% and 55% of the patients recovered to good function.27 The
RCT of treating mild sensory impairment found that a significant higher proportion improved
in the prednisolone group compared to the placebo group after 4 months, although the
difference disappeared by the 6 month follow-up.24 Another study found that it may take a
long time to achieve full recovery of chronic or recurrent NFI, at least much longer than the
duration of a standard steroid course.14 Recovery of nerve function loss is more likely when
the duration of NFI has been less than 6 months.2,3 To illustrate, data from Ethiopia showed
that patients with NFI for less than 6 months and treated with steroids had full recovery in 50
out of 57 nerves (88%), while in-patients with recurrent or chronic NFI only 20 out of 39
nerves (51%) had fully recovered after up to 10 years after treatment.14 This is in line with the
RCT of treating long-standing NFI which found that 19 out of 41 nerves (46%) treated with
prednisolone improved.25 However, even in the placebo group, 25 out of 51 nerves (49%)
showed spontaneous improvement after 12 months. Other studies also reported spontaneous
nerve function improvement in untreated individuals.12,14,15
The optimal corticosteroid regimen has not been established. Recommendations about the
optimal dose and duration of steroid therapy have changed over time.8,28 The principles of a
steroid therapy are that it should start with a dose that is sufficient to control the inflammation
rapidly. Then the dose should be tapered off until the reaction has settled. The ideal would be
a steroid course adjusted and tailored to the individual’s situation, but this may be only
possible in referral centres.29
Currently, a standard 12 week course of prednisolone is recommended by the WHO
which can be safely used in the field.5 Other studies have suggested that a prolonged regimen
might be more beneficial. One small retrospective study compared a short-term steroid
treatment (2 months) with a prolonged steroid treatment (3 to 18 months) for type 1 reaction
in borderline leprosy patients. It was found that the latter treatment gave better results on
improving motor nerve function than the shorter treatment and did not increase the risk of
adverse events. The critical dose to control a reaction after the initial period was considered to
be 15 to 20 mg daily.7 One study examined the effects of prednisolone treatment on the
cellularity and cytokine profiles of leprosy skin type 1 reactions. The results showed that
prednisolone treatment decreased cytokine levels significantly only after 28 days from the
start of treatment. Some patients continued to have cytokine production for 1 to 6 months.
This study illustrates the slow response to steroid therapy and continuing activity for several
months.6 While these non-randomised studies already suggested the benefits of a prolonged
steroid course, the RCT comparing three corticosteroid regimens confirms this in reporting
that a longer duration of prednisolone treatment gave less poor outcomes than a short course
of prednisolone.26
According to other authorities, a substantial proportion of individuals treated for nerve
damage do not respond to corticosteroids. The overall nerve function improvement levels
vary approximately between 60% and 80% after steroid therapy.12 This study reported that 27
out of 83 treated nerves with motor impairment (33%) and 53 out of 166 treated nerves with
sensory impairment (32%) did not improve or had deteriorated 12 months after the start of
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treatment. In a study in Thailand, 27 out of 77 patients who were treated with prednisolone
(35%) showed no improvement or a worsening of NFI.15 One randomised controlled trial
examined the effect of prophylactic use of steroids in 636 newly diagnosed multibacillary
patients.30 This study showed that a low dose prophylactic steroid regimen reduced the risk of
NFI at the end of 4 months, but the effect was not sustained at 1 year. Repeat use of steroid
prophylaxis for a longer period than 4 months may sustain the benefit, but this needs to be
further examined.
An alternative therapeutic approach for treating nerve damage in leprosy has been
surgical decompression of acutely inflamed nerves. There is an ongoing search for new
therapies, because steroids are not always effective, and may cause serious adverse effects
and because their long-term effect is unclear. A quasi-randomised controlled trial compared
an 8 week course of prednisolone combined with azathioprine with a 12 week course of
prednisolone alone for treating severe type 1 reactions.19 The trial did not find a significant
difference between the two treatment groups, but the study was limited in size (n ¼ 40).
A recent non-randomised follow-up study assessed the effects of ciclosporin treatment in
33 Ethiopian and 10 Nepali leprosy patients with severe type 1 reactions and the authors
suggested that ciclosporin monotherapy may be an effective treatment for severe type 1
reactions with few adverse effects.20 Therapies which are used for other immune-mediated
conditions, such as ciclosporin or combinations of immunosuppressants may be promising. It
is plausible that these therapies may be effective for treating nerve damage in leprosy, but
evidence from RCTs is lacking.1
Conclusion
IMPLICATIONS FOR PRACTICE
Evidence from the three randomised controlled trials is insufficient to draw robust
conclusions about the long-term effect of corticosteroids for treating nerve damage in
leprosy. Two trials, of which one treated long-standing nerve function impairment and the
other mild sensory impairment, did not show significantly better outcomes with
corticosteroids than placebo for treating nerve damage in leprosy in the long term. However
in a third trial, a 5 month corticosteroid regimen was significantly more beneficial than a
3 month corticosteroid regimen. Standard corticosteroid regimens are not significantly more
harmful than placebo treatment, despite known adverse effects of corticosteroids.
IMPLICATIONS FOR RESEARCH
There is a need for high-quality randomised controlled trials to establish the value and
optimal dose of corticosteroid regimens and to examine the efficacy and safety of new
therapies. Future trials should pay more attention to non-clinical aspects, such as costs and
impact on quality of life, because these are highly relevant indicators for both policy makers
and participants.
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